The European Innovation Council’s (EIC) Transition call has chosen Cambridge Raman Imaging, or CRI, to lead CHARM. In order to do this, the project itself has received a €3.3 million grant, of which CRI directly get to keep €1.3 million for their own research and contributions.
CHARM, as you may have guessed, is a project dedicated towards contributing to cancer curing technology. The goal is to make technology that is not only low cost and easily accessible, but high speed and efficient, even utilizing digital imaging technology and artificial intelligence. The medical equipment will make the identification of cancerous cells in a body that much faster, as it is able to distinguish between healthy and unhealthy without the use of chemical straining (a process that isn’t very time or cost sensitive). To achieve this, graphene technology is used in order to utilize ultra-fast fiber lasers that scan and transcribe their findings into digital images, which can then be reviewed. Because this is a digital process, patients don’t necessarily have to be in close proximity of their desired doctors; only close to the machine that can perform the scan and then upload it.
CHARM itself is a collaboration of companies throughout the entirety of Europe, featuring RI, the University of Cambridge, Italian institutions Politecnico Di Milano and Consiglio Nazionale Delle Ricerche, the Jena University Hospital in Germany, and the firms INsociety from Italy and Inspiralia from Spain. At the head of it all is Dr. Matteo Negro, who’s CRI’s Chief Technology Officer.